[1] Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international antiviral society–USA panel. JAMA, 2012; 308, 387−402.
[2] Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med, 2016; 375, 830−9. doi:  10.1056/NEJMoa1600693
[3] Zhao DC, Wen Y, Ma Y, et al. Expansion of China’s free antiretroviral treatment program. Chin Med J, 2012; 129, 3514−21.
[4] China M O H O. Guidelines for diagnosis and treatment of AIDS. Word Clin Drugs, 2005; 26, 454−9. (In Chinese
[5] Zhang FJ, Zhao Y, Ma Y, et al. Progress and achievements of free antiretroviral treatment for AIDS in China. Chin J AIDS STD, 2022; 28, 6−9. (In Chinese
[6] Hao Y, Chen QF, Han MJ, et al. The initiation and development of free antiretroviral treatment for AIDS in China - a path of antiretroviral treatment with Chinese characteristics. Chin J AIDS STD, 2022; 28, 1−5. (In Chinese
[7] Blassel L, Zhukova A, Villabona-Arenas CJ, et al. Drug resistance mutations in HIV: new bioinformatics approaches and challenges. Curr Opin Virol, 2021; 51, 56−64. doi:  10.1016/j.coviro.2021.09.009
[8] Zuo LL, Liu K, Liu HL, et al. Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001-2017). eClinicalMedicine, 2020; 18, 100238. doi:  10.1016/j.eclinm.2019.100238
[9] Guo CX, Wu YX, Zhang Y, et al. Transmitted drug resistance in antiretroviral therapy-naive persons with acute/early/primary HIV infection: a systematic review and meta-analysis. Front Pharmacol, 2021; 12, 718763. doi:  10.3389/fphar.2021.718763
[10] Lan Y, Deng XZ, Li LH, et al. HIV-1 drug resistance and genetic transmission networks among MSM failing antiretroviral therapy in South China 2014-2019. Infect Drug Resist, 2021; 14, 2977−89. doi:  10.2147/IDR.S317187
[11] Zou XB, He JM, Zheng J, et al. Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China. Virol J, 2020; 17, 38. doi:  10.1186/s12985-020-01311-3
[12] Lu XL, Zhao HR, Zhang YQ, et al. HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China. AIDS Res Ther, 2017; 14, 4. doi:  10.1186/s12981-017-0133-3
[13] Gardner EM, Burman WJ, Steiner JF, et al. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS, 2009; 23, 1035−46. doi:  10.1097/QAD.0b013e32832ba8ec
[14] Zhang FD, Liu L, Sun MY, et al. An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China. PLoS One, 2017; 12, e0165110. doi:  10.1371/journal.pone.0165110
[15] Yan LT, Yu FT, Liang JM, et al. Drug resistance profiles and influencing factors among HIV-infected children and adolescents receiving long-term ART: a multicentre observational study in China. J Antimicrob Chemother, 2022; 77, 727−34. doi:  10.1093/jac/dkab430
[16] Musema GMA, Akilimali PZ, Za Balega TKN, et al. Predictive factors of HIV-1 drug resistance and its distribution among female sex workers in the Democratic Republic of the Congo (DRC). Int J Environ Res Public Health, 2022; 19, 2021. doi:  10.3390/ijerph19042021
[17] Omooja J, Nannyonjo M, Sanyu G, et al. Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda. J Antimicrob Chemother, 2019; 74, 3021−9. doi:  10.1093/jac/dkz261
[18] WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. WHO. 2016.
[19] Zhao ZY. The analysis of the willingness to reside of Hainan's floating population and it's influencing factors. Jilin University. 2020. (In Chinese)
[20] Wang Y. A study on the health problems and the influencing factors of climate migrant population in winter in Sanya city. Chinese Center for Disease Control and Prevention. 2017. (In Chinese)
[21] Feng YT, Xu YJ, Ma YR, et al. Epidemiology characteristics among HIV/AIDS patients receiving initial antiretroviral therapy in Hainan, 2005-2019. China Trop Med, 2021; 21, 681−5. (In Chinese
[22] Zeng XM, Fu P, Wang ZQ, et al. Analysis on the characteristics and transmission routes of AIDS epidemic in Hainan. China Trop Med, 2020; 20, 735−8. (In Chinese
[23] Ma J, Tong X, Hui S, et al. Analysis on HIV/AIDS Epidemic Situation in HeiLongJiang Province From 2012 to 2017. Harbin Med J, 2018; 38, 222−4. (In Chinese
[24] Yu L, Hui S, Li T, et al. Epidemiological characteristics of AIDS patients receiving free antiviral treatment for the first in Heilongjiang, 2014-2018. Chin J Public Health Manag, 2019; 35, 375−7. (In Chinese
[25] Zhou JL, Wang L, Zhou D, et al. Prevalence characteristics of HIV/AIDS in Liaoning province, 1993 to 2015. Chin J Public Health, 2017; 33, 1209−12. (In Chinese
[26] Chen RF, Liang BY, Wen BB, et al. No difference in prevalence of transmitted drug resistance between injection drug users and non-injection drug users: a cross-sectional study among antiretroviral treatment-naïve HIV patients. Intervirology, 2018; 61, 281−91. doi:  10.1159/000499367
[27] Dou ZZ, Zhang FJ, Zhao Y, et al. Progress on China’s national free antiretroviral therapy strategy in 2002-2014. Chin J Epidemiol, 2015; 36, 1345−50. (In Chinese
[28] Kyaw NTT, Harries AD, Kumar AMV, et al. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005-2015. PLoS One, 2017; 12, e0171780. doi:  10.1371/journal.pone.0171780
[29] Tran DA, Wilson DP, Shakeshaft A, et al. Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces. Sex Transm Infect, 2014; 90, 538−44. doi:  10.1136/sextrans-2013-051353
[30] Bulage L, Ssewanyana I, Nankabirwa V, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014-July 2015. BMC Infect Dis, 2017; 17, 326. doi:  10.1186/s12879-017-2428-3
[31] Alave J, Paz J, González E, et al. Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru. Rev Chilena Infectol, 2013; 30, 42−8. doi:  10.4067/S0716-10182013000100006
[32] Louis FJ, Buteau J, François K, et al. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. PLoS One, 2018; 13, e0192077. doi:  10.1371/journal.pone.0192077
[33] Deng W, Fu P, Bao LL, et al. Molecular epidemiological tracing of HIV-1 outbreaks in Hainan island of southern China. AIDS, 2009; 23, 977−85. doi:  10.1097/QAD.0b013e328329217d
[34] Chu MJ, Zhang WH, Zhang X, et al. HIV-1 CRF01_AE strain is associated with faster HIV/AIDS progression in Jiangsu Province, China. Sci Rep, 2017; 7, 1570. doi:  10.1038/s41598-017-01858-2
[35] Jordan MR, Bennett DE, Wainberg MA, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis, 2012; 54 Suppl 4, S245-9.
[36] Dong K, Ye L, Leng Y, et al. Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Sichuan, China, 2010-2016. Tohoku J Exp Med, 2019; 247, 1−12. doi:  10.1620/tjem.247.1
[37] Zuo ZB, Liang S, Sun XG, et al. Drug resistance and Virological failure among HIV-infected patients after a decade of antiretroviral treatment expansion in eight provinces of China. PLoS One, 2016; 11, e0166661. doi:  10.1371/journal.pone.0166661
[38] Chimukangara B, Lessells RJ, Singh L, et al. Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa. AIDS Res Ther, 2021; 18, 74. doi:  10.1186/s12981-021-00393-5
[39] Santos-Pereira A, Triunfante V, Araujo PMM, et al. Nationwide study of drug resistance mutations in HIV-1 infected individuals under antiretroviral therapy in Brazil. Int J Mol Sci, 2021; 22, 5304. doi:  10.3390/ijms22105304
[40] Arimide DA, Amogne MD, Kebede Y, et al. High level of HIV drug resistance and Virologic Nonsuppression among female sex workers in Ethiopia: a nationwide cross-sectional study. J Acquir Immune Defic Syndr, 2022; 89, 566−74. doi:  10.1097/QAI.0000000000002908
[41] Shchemelev AN, Ostankova YV, Zueva EB, et al. Detection of patient HIV-1 drug resistance mutations in Russia's northwestern federal district in patients with treatment failure. Diagnostics, 2022; 12, 1821. doi:  10.3390/diagnostics12081821
[42] Cauldbeck MB, O'connor C, O'connor MB, et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther, 2009; 6, 7. doi:  10.1186/1742-6405-6-7
[43] Suryana K, Suharsono H, Antara IGPJ. Factors associated with adherence to anti-retroviral therapy among people living with HIV/AIDS At Wangaya hospital in Denpasar, Bali, Indonesia: a cross-sectional study. HIV AIDS, 2019; 11, 307−12.
[44] Etiebet MAA, Shepherd J, Nowak RG, et al. Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. AIDS, 2013; 27, 553−61. doi:  10.1097/QAD.0b013e32835b0f59
[45] Margot N, Lu B, Cheng A, et al. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med, 2006; 7, 442−50. doi:  10.1111/j.1468-1293.2006.00404.x
[46] Guo XL, Zhang F, Liu XX, et al. Analysis of HIV-1 genotype resistance test of HIV antiviral therapy failures, 2019-2020, in Shanxi province. Chin J Exp Clin Virol, 2022; 36, 176−82. (In Chinese
[47] Henerico S, Mikasi SG, Kalluvya SE, et al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. J Antimicrob Chemother, 2022; 77, 483−91. doi:  10.1093/jac/dkab406
[48] Scriven YA, Mulinge MM, Saleri N, et al. Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study. Medicine, 2021; 100, e27460. doi:  10.1097/MD.0000000000027460
[49] Yu DE, Liang BY, Yang Y, et al. Prevalence of drug resistance and genetic transmission networks among human immunodeficiency virus/acquired immunodeficiency syndrome patients with antiretroviral therapy failure in Guangxi, China. AIDS Res Hum Retroviruses, 2022; 38, 822−30. doi:  10.1089/aid.2021.0181
[50] La Rosa AM, Harrison LJ, Taiwo B, et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV, 2016; 3, e247−58. doi:  10.1016/S2352-3018(16)30011-X
[51] Reuman EC, Rhee SY, Holmes SP, et al. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Antimicrob Chemother, 2010; 65, 1477−85. doi:  10.1093/jac/dkq140
[52] Melikian GL, Rhee SY, Varghese V, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother, 2014; 69, 12−20. doi:  10.1093/jac/dkt316
[53] CDC. National free AIDS ART guideline. 4th ed. People's Health Publishing House. 2016. (In Chinese)
[54] Kulkarni R, Babaoglu K, Lansdon EB, et al. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to Rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr, 2012; 59, 47−54.
[55] Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS, 2004; 18, 1691−6. doi:  10.1097/01.aids.0000131355.44834.e4
[56] Gagliardini R, Ciccullo A, Borghetti A, et al. Impact of the M184V resistance mutation on Virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study. Open Forum Infect Dis, 2018; 5, ofy113. doi:  10.1093/ofid/ofy113
[57] Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2000; 44, 920−8. doi:  10.1128/AAC.44.4.920-928.2000
[58] Ayitewala A, Kyeyune F, Ainembabazi P, et al. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda. AIDS Res Ther, 2020; 17, 2. doi:  10.1186/s12981-020-0258-7
[59] Zaccarelli M, Tozzi V, Lorenzini P, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS, 2005; 19, 1081−9. doi:  10.1097/01.aids.0000174455.01369.ad
[60] Lombardi F, Giacomelli A, Armenia D, et al. Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database. Int J Antimicrob Agents, 2021; 57, 106252. doi:  10.1016/j.ijantimicag.2020.106252